| Dr Theodore William Vanderhorst, DO | |
|
700 West Ave S, La Crosse, WI 54601-4783 | |
| (608) 785-0940 | |
| (608) 392-7197 |
| Full Name | Dr Theodore William Vanderhorst |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 14 Years |
| Location | 700 West Ave S, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336468362 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | R - 8887 (Iowa) | Secondary |
| 207L00000X | Anesthesiology | 62064 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System-franciscan Medical Center Inc | La crosse, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-franciscan Medical Center Inc | 0345152443 | 419 |
News Archive
In this post in the Public Health Institute's "Dialogue4Health" blog, Jeffrey Meer, director of PHI's Washington-based advocacy on global health, writes that "a significant expansion of PEPFAR's existing work to combat cervical cancer" through a partnership with the George W. Bush Institute known as Pink Ribbon Red Ribbon (PRRR); a 50 percent increase in the U.S. government's "commitment to screen and treat for this type of cancer from $20 million over five years to $30 million"; and additional funding from Susan G. Komen for the Cure "to expand breast cancer awareness and prevention among the same target population of women receiving care at PEPFAR-funded HIV service sites" has allowed "the wonderfully robust PEPFAR prevention and treatment platform, considered one of the great global health achievements in recent times, to be made available to a whole new type of prevention - in this case for a non-communicable disease (NCD)."
EffRx Pharmaceuticals SA and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.
Gene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.
Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629056049 PECOS PAC ID: 0345152443 Enrollment ID: O20031110000684 |
News Archive
In this post in the Public Health Institute's "Dialogue4Health" blog, Jeffrey Meer, director of PHI's Washington-based advocacy on global health, writes that "a significant expansion of PEPFAR's existing work to combat cervical cancer" through a partnership with the George W. Bush Institute known as Pink Ribbon Red Ribbon (PRRR); a 50 percent increase in the U.S. government's "commitment to screen and treat for this type of cancer from $20 million over five years to $30 million"; and additional funding from Susan G. Komen for the Cure "to expand breast cancer awareness and prevention among the same target population of women receiving care at PEPFAR-funded HIV service sites" has allowed "the wonderfully robust PEPFAR prevention and treatment platform, considered one of the great global health achievements in recent times, to be made available to a whole new type of prevention - in this case for a non-communicable disease (NCD)."
EffRx Pharmaceuticals SA and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.
Gene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.
Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1841278637 PECOS PAC ID: 0345152443 Enrollment ID: O20100506000523 |
News Archive
In this post in the Public Health Institute's "Dialogue4Health" blog, Jeffrey Meer, director of PHI's Washington-based advocacy on global health, writes that "a significant expansion of PEPFAR's existing work to combat cervical cancer" through a partnership with the George W. Bush Institute known as Pink Ribbon Red Ribbon (PRRR); a 50 percent increase in the U.S. government's "commitment to screen and treat for this type of cancer from $20 million over five years to $30 million"; and additional funding from Susan G. Komen for the Cure "to expand breast cancer awareness and prevention among the same target population of women receiving care at PEPFAR-funded HIV service sites" has allowed "the wonderfully robust PEPFAR prevention and treatment platform, considered one of the great global health achievements in recent times, to be made available to a whole new type of prevention - in this case for a non-communicable disease (NCD)."
EffRx Pharmaceuticals SA and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.
Gene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.
Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Theodore William Vanderhorst, DO 700 West Ave S, La Crosse, WI 54601-4783 Ph: (608) 785-0940 | Dr Theodore William Vanderhorst, DO 700 West Ave S, La Crosse, WI 54601-4783 Ph: (608) 785-0940 |
News Archive
In this post in the Public Health Institute's "Dialogue4Health" blog, Jeffrey Meer, director of PHI's Washington-based advocacy on global health, writes that "a significant expansion of PEPFAR's existing work to combat cervical cancer" through a partnership with the George W. Bush Institute known as Pink Ribbon Red Ribbon (PRRR); a 50 percent increase in the U.S. government's "commitment to screen and treat for this type of cancer from $20 million over five years to $30 million"; and additional funding from Susan G. Komen for the Cure "to expand breast cancer awareness and prevention among the same target population of women receiving care at PEPFAR-funded HIV service sites" has allowed "the wonderfully robust PEPFAR prevention and treatment platform, considered one of the great global health achievements in recent times, to be made available to a whole new type of prevention - in this case for a non-communicable disease (NCD)."
EffRx Pharmaceuticals SA and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.
Gene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.
Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.
› Verified 7 days ago
Jeffrey Brian Trohkimoinen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, Gundersen Clinic, Ltd., La Crosse, WI 54601 Phone: 608-775-2031 | |
Robert R Groshek, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Kaytie M Curtis, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Richard A Olson, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Joon Yoon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Dr. Laura Beth Zitelman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Stephanie Ann Neuman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |